The Effects of His Bundle Pacing Compared to Classic Resynchronization Therapy in Patients with Pacing-Induced
Rafal Gardas1,2, Krzysztof S Golba1,2, Tomasz Soral1
1Department of Electrocardiology, Leszek Giec Upper-Silesian Medical Centre, Silesian Medical University, 40-055 Katowice, Poland.
Insights
His bundle pacing (HBP) offers a superior alternative to biventricular pacing (BVP) for patients with pacing-induced cardiomyopathy (PICM) undergoing cardiac resynchronization therapy (CRT) upgrades. HBP demonstrated greater improvements in QRS duration, clinical outcomes, and left ventricular function.
Area of Science:
- Cardiology
- Electrophysiology
- Cardiovascular Medicine
Background:
- Pacing-induced cardiomyopathy (PICM) is a common complication of right ventricular pacing.
- Cardiac resynchronization therapy (CRT) is the recommended treatment for PICM.
- His bundle pacing (HBP) offers a potential alternative to biventricular pacing (BVP) by restoring synchronous ventricular activation.
Purpose of the Study:
- To evaluate the efficacy of His bundle pacing (HBP) compared to biventricular pacing (BVP) in patients with pacing-induced cardiomyopathy (PICM) undergoing cardiac resynchronization therapy (CRT) upgrade.
- To assess improvements in electrocardiographic, clinical, and echocardiographic parameters following HBP versus BVP.
Main Methods:
- A prospective cohort study included patients with PICM scheduled for CRT upgrade.
- Patients received either His bundle pacing (HBP) or biventricular pacing (BVP).
- Measurements of QRS duration, New York Heart Association (NYHA) class, left ventricular ejection fraction (LVEF), and left ventricle reverse remodeling were recorded at baseline and six-month follow-up.
Main Results:
- His bundle pacing (HBP) was successful in 83% of patients.
- HBP resulted in a significantly greater reduction in QRS duration compared to BVP (118.3 ms vs. 150.5 ms).
- Improvements in NYHA class, LVEF, and left ventricle reverse remodeling were more pronounced with HBP than with BVP.
Conclusions:
- His bundle pacing (HBP) is a viable and effective alternative to biventricular pacing (BVP) for cardiac resynchronization therapy (CRT) upgrades in patients with pacing-induced cardiomyopathy (PICM).
- HBP facilitates more significant improvements in ventricular synchrony, clinical status, and cardiac structure compared to BVP.
Abstract:
Pacing-induced cardiomyopathy (PICM) is among the most common right ventricular pacing complications. Upgrading to cardiac resynchronization therapy (CRT) is the recommended treatment option. Conduction system pacing with His bundle pacing (HBP) has the potential to restore synchronous ventricular activation and can be an alternative to biventricular pacing (BVP). Patients with PICM scheduled for a system upgrade to CRT were included in the prospective cohort study. Either HBP or BVP was used for CRT. Electrocardiographic, clinical, and echocardiographic measurements were recorded at baseline and six-month follow-up. HBP was successful in 44 of 53 patients (83%). Thirty-nine patients with HBP and 22 with BVP completed a 6-month follow-up. HBP led to a higher reduction in QRS duration than BVP, 118.3 ± 14.20 ms vs. 150.5 ± 18.64 ms, p < 0.0001. The improvement in New York Heart Association (NYHA) class by one or two was more common in patients with HBP than those with BiV (p = 0.04). Left ventricular ejection fraction (LVEF) improved in BVP patients from 32.9 ± 7.93% to 43.9 ± 8.07%, p < 0.0001, and in HBP patients from 34.9 ± 6.45% to 48.6 ± 7.73%, p < 0.0001. The improvement in LVEF was more considerable in HBP patients than in BVP patients, p = 0.019. The improvement in clinical outcomes and left ventricle reverse remodeling was more significant with HBP than BVP. HBP can be a valid alternative to BVP for upgrade procedures in PICM patients.
Related Concept Videos
Dysrhythmias VI: Management of Dysrhythmias
Dysrhythmias IV: Characteristics of Bradyarrhythmias
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiopulmonary Resuscitation IV: Pharmacological Management
Cardiomyopathy IV: Restrictive Cardiomyopathy
Heart Failure Drugs: Inotropic Agents


